SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.
Company profile
Ticker
SPNE
Exchange
Website
CEO
Keith Valentine
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
IsoTis International SARL • IsoTis OrthoBiologics, Inc. • IosTis, Inc. • SeaSpine, Inc. • SeaSpine Sales LLC • SeaSpine Orthopedics Corporation • Theken Spine, LLC • SeaSpine Orthopedics IntermediateCo, Inc. • Project Maple Leaf Holdings ULC • 7D Surgical ULC ...
SPNE stock data
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
3 Apr 23
15-12G
Securities registration termination
17 Jan 23
EFFECT
Notice of effectiveness
12 Jan 23
EFFECT
Notice of effectiveness
12 Jan 23
EFFECT
Notice of effectiveness
12 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Jan 23
Transcripts
SPNE
Earnings call transcript
2022 Q3
2 Nov 22
SPNE
Earnings call transcript
2022 Q2
3 Aug 22
SPNE
Earnings call transcript
2022 Q1
4 May 22
SPNE
Earnings call transcript
2021 Q3
29 Oct 21
SPNE
Earnings call transcript
2021 Q2
3 Aug 21
SPNE
Earnings call transcript
2021 Q1
4 May 21
SPNE
Earnings call transcript
2020 Q4
2 Mar 21
SPNE
Earnings call transcript
2020 Q3
9 Nov 20
SPNE
Earnings call transcript
2020 Q2
8 Aug 20
SPNE
Earnings call transcript
2020 Q1
13 May 20
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 46.76 mm | 46.76 mm | 46.76 mm | 46.76 mm | 46.76 mm | 46.76 mm |
Cash burn (monthly) | 6.44 mm | 4.64 mm | 5.04 mm | 5.52 mm | 3.69 mm | 3.78 mm |
Cash used (since last report) | 115.59 mm | 83.29 mm | 90.43 mm | 99.10 mm | 66.24 mm | 67.81 mm |
Cash remaining | -68.83 mm | -36.53 mm | -43.67 mm | -52.34 mm | -19.47 mm | -21.04 mm |
Runway (months of cash) | -10.7 | -7.9 | -8.7 | -9.5 | -5.3 | -5.6 |
Institutional ownership, Q1 2023
5.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 112 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 2.00 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tru St Partnership | 2.00 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Jan 23 | Paul S. Benny | Common Stock | Sale back to company | Dispose D | No | No | 0 | 20,950 | 0.00 | 0 |
5 Jan 23 | Paul S. Benny | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.67 | 6,906 | 87.50 k | 0 |
5 Jan 23 | Paul S. Benny | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16.86 | 5,925 | 99.90 k | 0 |
5 Jan 23 | Paul S. Benny | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.93 | 2,716 | 26.97 k | 0 |
5 Jan 23 | Paul S. Benny | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.01 | 10,398 | 124.88 k | 0 |
5 Jan 23 | Paul S. Benny | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 18.24 | 3,423 | 62.44 k | 0 |
5 Jan 23 | Paul S. Benny | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 14.19 | 8,800 | 124.87 k | 0 |
5 Jan 23 | Paul S. Benny | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 15.68 | 10,000 | 156.80 k | 0 |
5 Jan 23 | Paul S. Benny | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 2,762 | 0.00 | 0 |
5 Jan 23 | Paul S. Benny | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 1,186 | 0.00 | 0 |